ClearPoint Neuro, Inc. (NASDAQ:CLPT - Get Free Report)'s share price hit a new 52-week high on Thursday . The stock traded as high as $19.22 and last traded at $18.58, with a volume of 16118 shares. The stock had previously closed at $18.80.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on CLPT shares. B. Riley increased their price target on ClearPoint Neuro from $15.00 to $20.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. Lake Street Capital increased their target price on ClearPoint Neuro from $17.00 to $30.00 and gave the stock a "buy" rating in a research report on Tuesday, January 21st.
Check Out Our Latest Research Report on CLPT
ClearPoint Neuro Price Performance
The stock has a market cap of $500.85 million, a P/E ratio of -26.32 and a beta of 1.03. The stock's 50-day moving average is $15.87 and its two-hundred day moving average is $12.90.
ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The company had revenue of $8.12 million for the quarter, compared to the consensus estimate of $8.07 million. During the same period last year, the company earned ($0.20) EPS. On average, analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 EPS for the current fiscal year.
Institutional Trading of ClearPoint Neuro
Large investors have recently added to or reduced their stakes in the company. AlphaQuest LLC purchased a new position in shares of ClearPoint Neuro in the fourth quarter valued at $80,000. Bradley Foster & Sargent Inc. CT purchased a new position in shares of ClearPoint Neuro in the 4th quarter worth $871,000. R Squared Ltd bought a new stake in shares of ClearPoint Neuro in the 4th quarter worth about $32,000. Parsons Capital Management Inc. RI raised its position in shares of ClearPoint Neuro by 1.9% during the 4th quarter. Parsons Capital Management Inc. RI now owns 141,573 shares of the company's stock valued at $2,177,000 after buying an additional 2,600 shares in the last quarter. Finally, Conway Capital Management Inc. lifted its holdings in shares of ClearPoint Neuro by 13.9% in the 4th quarter. Conway Capital Management Inc. now owns 161,225 shares of the company's stock valued at $2,480,000 after acquiring an additional 19,725 shares during the last quarter. Institutional investors own 30.08% of the company's stock.
ClearPoint Neuro Company Profile
(
Get Free Report)
ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.
See Also
Before you consider ClearPoint Neuro, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ClearPoint Neuro wasn't on the list.
While ClearPoint Neuro currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
